For instance, the GORTEC 2017-01 (REACH) Phase III trial (NCT02999087) is evaluating the efficacy and safety of combining cetuximab and avelumab (anti-PD-L1) with radiotherapy versus standard radiotherapy combinations in locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) [57]. Here, CD274 is linked to head and neck squamous cell carcinoma.